Recent work highlights the potential usefulness of MVMbased vectors as selective vehicles for cancer gene therapy (Dupont et al, Gene Therapy, 2000; 7: 790-796). To implement this strategy, however, it is necessary to develop optimized methods for producing high-titer, helper-free parvovirus stocks. Recombinants of MVMp (rMVMp) are currently generated by transiently co-transfecting permissive cell lines with a plasmid carrying the vector genome and a helper plasmid expressing the capsid genes (replaced with a foreign gene in the vector genome). The resulting stocks, however, are always heavily contaminated with replicationcompetent viruses (RCV), which precludes their use in vivo and particularly in gene therapy. In the present work we have developed a second-generation MVMp-based vector system specifically designed to reduce the probability of RCV generation by homologous recombination. We have constructed a new MVMp-based vector and a new helper genome with minimal sequence overlap and have used the degeneracy of the genetic code to further decrease vector-
Introduction
The fibrotropic strain of minute virus of mice (MVMp), a nonpathogenic autonomous parvovirus with oncotropic properties, has been successfully used in vitro to specifically target reporter or effector gene expression in human tumor cells of various tissue origins. [1] [2] [3] This attractive oncospecific transduction ability of MVMp-based vectors suggests the possibility of using them as selective vehicles for tumor-cell-targeted gene therapy. 4 This makes it necessary to develop optimized methods for producing high-titer, helper-free parvoviral preparations. Recombinants of MVMp (rMVMp) are created by inserting a foreign gene in place of the capsid-encoding region of the infectious genomic clone of MVMp, plasmid pMM984, 5 under the control of the late P38 promoter (Figure 1b) . Relatively high-titer recombinant virus stocks helper homology. In this system, the left homologous region was almost completely eliminated and the right sequence overlap was reduced to 74 nt with only 61% homology. We were thus able to substantially reduce (ෂ200 ×), but not completely eliminate, generation of contaminating viruses in medium-scale rMVMp preparations. Since the remaining sequence homology between the new vector and helper genomes is weak, our results suggest that contaminating viruses in this system are generated by nonhomologous recombination. It is important to note, unlike the autonomously replicating helper viruses produced from the firstgeneration vector/helper genomes, the contaminating viruses arising from the new packaging system cannot initiate secondary infection rounds (so they are not 'replication-competent viruses'). Our findings have important implications for the design of new MVMp-based vectors and for the construction of trans-complementing packaging cell lines. Gene Therapy (2001) 8, 921-929.
(ෂ10 9 infectious units (IU)/ml) 6 are currently produced by transiently co-transfecting permissive COS-7 cells, a SV40-transformed simian cell line, with a plasmid carrying the vector genome and a helper plasmid expressing the capsid genes (pSP116, Figure 1b) .
One limitation of current rMVMp preparations is their high level of contamination (ෂ10 to 80% of the vector stock) by replication-competent viruses (RCV). 1,2,7 As described for other viral vector systems (including vectors based on other autonomous parvoviruses as Lu III and H1), RCV are generated by recombination between overlapping sequences shared by the vector and helper genomes ( Figure 1b ). [8] [9] [10] [11] [12] One approach towards solving the problem of RCV contamination might consist in constructing a packaging cell line carrying the helper construct integrated into the chromosomal DNA. This strategy is based on the observation that plasmids are more recombinogenic when multiple copies are present in transiently transfected cells than when a few copies are integrated into the host-cell DNA. 13 Brandenburger and Russell 14 have used this strategy to construct a first-generation packaging cell line for Tam and Astell. 17 The producing MVMp-based vectors. By transiently transfecting this cell line with a vector plasmid, they could indeed produce low-titer rMVMp stocks (ෂ5 × 10 3 IU per ml of crude cell lysate) containing no detectable RCV. However, although it was possible to significantly increase rMVMp yield by serial infection rounds in a similar firstgeneration packaging cell line, this invariably gave rise to the concomitant appearance and subsequent massive amplification of RCV. 7 RCV have appeared in similar situations such as in first-generation packaging cell lines for retroviral vector. 8 The presence of significant amounts of contaminating RCV in vector stocks raises a problem of biosafety and may pose different practical problems. More precisely, it may interfere with vector production and complicate the interpretation of transduction results. Moreover, the appearance of RCV impedes the safe use of stable, transcomplementing packaging cell lines and the set-up of large-scale vector production methods, a crucial technological issue for considering the exploitation of oncotropic autonomous parvovirus-based vectors as a relevant alternative tool for cancer gene therapy.
Figure 1 (a) Genetic map of MVMp (not to scale). The MVMp genome (5146 bp) is indicated as a thick horizontal line with the 3Ј end of the ss (−) virion DNA on the left. Open boxes bracketing the viral DNA represent the palindromic DNA termini. ↑ and ↓ respectively show the locations of the two viral promoters (P4 and P38) and MVMp polyadenylation site. ᭺ represents the VP STOP codon. The thin open and solid boxes below the viral genome represent cis-acting replication elements (a) and (b) described by
From the foregoing, it is very important to provide a second-generation vector and helper system for producing MVMp-based vectors that does not result in the generation of RCV. We describe in this report the construction of new complementary vector and helper genomes specifically designed to reduce the probability of generating RCV by homologous recombination. We show that the use of this new packaging system allows significant reduction in the production of contaminating, helperderived viruses (ෂ200 ×) in purified, concentrated medium-scale rMVMp preparations (ෂ5 × 10 7 IU/ml). Most important, we further demonstrate, by means of a sensitive sequential amplification assay, that these contaminating viruses are not competent for autonomous replication. This work might significantly improve the further development of MVMp-based vectors, since it would allow the establishment of second-generation packaging cell lines and the set-up of large-scale vector production methods in the near future.
Results
Construction of newly designed vector and helper genomes with minimal sequence homology In plasmids pFD44 and pSP116, the first generation vector and helper genomes, the left homologous region consists in a 797 nt sequence containing different overlapping functional domains ( Figure 1b ): (1) the P38 promoter; (2) the 3Ј end of the NS1 gene and the second NS2 exon; (3) the small central intron which undergoes an alternative splicing to allow the differential translation of VP1, VP2 and the three isoforms of NS2 15, 16 and (4) a region which runs to the start of the transgene and includes the 5Ј non-translated sequence of the R transcripts and the 5Ј end of the second VP1 exon.
The right homologous region consists of 286 nucleotides comprising the 3Ј end of the capsid genes ( Figure  1b ). This region also carries a cis-acting element that has been reported to be required for efficient viral DNA replication. 17, 18 In order to minimize/suppress the likelihood of recombination, a second-generation vector/helper system with minimal overlapping sequences has been designed. This was done by physically separating as much as possible the viral genetic determinants required for the helper function (the capsid-protein-encoding genes) from those essential to the vector function (ie the remainder of the MVMp genome including both genomic ends, the regulatory NS genes, and the P38 promoter). The work proved particularly difficult because of extensive overlapping between the viral coding sequences and the genetic elements required in cis for the replication, regulation of gene expression, and packaging of the viral DNA.
Construction of the new helper genome: The 5Ј and 3Ј nontranslated sequences of capsid genes were eliminated and the capsid-protein coding sequences were placed under control of exogenous transcriptional signals. The resulting plasmid, pHVR4, is represented in Figure 1d . In this construct, the major splice donor site (nt 2280) of the small central intron was placed just downstream to the cytomegalovirus (CMV) immediate-early promoter and the VP1-2 termination codon was located just upstream to the SV40 polyadenylation signal.
A sequence at the 3Ј end of the capsid genes (and thus required for the helper function) was proved necessary in cis for efficient vector DNA replication (see below). It was therefore necessary to maintain a 3Ј sequence overlap between the vector and helper genomes, because vector DNA replication is required for the proper functioning of the recombinant virus, particularly to ensure packaging of the parvoviral genome into viral particles. To reduce sequence homology in this region, we exploited the degeneracy of the genetic code to modify the 3Ј-end primary sequence of the capsid genes in the helper genome. This 'codon wobbling' strategy was previously successfully used to reduce the probability of recombination in different vector systems, for example between gag-pol and env packaging constructs in the ⍀E packaging cell line for the production of MoMuLVderived vectors. 19 To replace the original codons, we chose synonymous codons used elsewhere in the MVMp genome. This strategy enabled us to reduce overall homology with the corresponding sequence of the vector DNA to ෂ60%. A 230-bp sequence comprising the altered, synonymous form of the MVMp sequence from nt 4343 (XbaI site) to nt 4557 (STOP codon of VP genes) was synthesized (see Materials and methods for further details) and inserted in pHVR4 in place of the corresponding wild-type (wt) sequence, generating the final helper construct pHVR5 (Figure 1d ). Figure 2a shows both the wt and the degenerated nucleotides sequence of the right, 74-bp-long overlap remaining in the new helper/vector genomes.
Construction of the new vector genome:
To eliminate the left homology, we inserted the transgene in the vector directly downstream to the STOP codon of NS1 ( Figure  1c ). The resulting vector plasmid (pME3) contained the P38 promoter and the entire NS1 gene, but lacked the small central intron and the third exon of the major form of NS2. 15, 16 In this construct, the second exon of NS2 was fused to the 5Ј terminus of the transgene (the CAT reporter gene), but in another open reading frame, so that the terminal part of NS2 is composed of 14 different amino acids. In pME3, the left overlap with the new helper genome was thereby reduced to only 3 bp (Figure 2b ).
Since analysis of defective interfering particles has shown that the cis-acting sequences required for DNA replication are mainly present in the terminal palindromic sequences of the MVMp genome, 20 we first attempted to completely eliminate the right homology by constructing pMN10, a recombinant vector in which the sequence carrying the 3Ј end of capsid genes was removed ( Figure 1c ). However, this plasmid was defective for virus DNA replication (see below). This tallies with the data of Tam and Astell, 17, 18 who identified cisacting replication signals inboard of the right hairpin Gene Therapy . This region has been shown to bind four cell proteins presumably involved in replication of MVMp DNA. 18 We therefore constructed a new recombinant with minimal right sequence overlap while keeping the replication elements described by Tam and Astell. A DNA fragment (MVMp nts 4480 to 4737) containing both replication elements was synthesized by PCR and inserted into the deletion site of pMN10, producing plasmid pMN18 (Figure 1c ). In this vector construct, the right sequence overlap with the new helper genome was reduced to 74 nucleotides ( Figure 2a ). The final vector genome, pMN33, was obtained by cumulating the left and right genetic modifications in the same construct. In this final construct, the left homologous region was almost completely eliminated (three overlapping nucleotides) and the right sequence overlap was reduced to 74 nt with only 61% homology ( Figure 2 ).
Functional analysis of the new helper and vector genomes
To assess the efficacy of the new helper construct, we compared the abilities of the pHVR4 and pSP116 helper plasmids to produce rMVMp. To this end, small-scale rMVMp stocks were produced by transiently transfecting COS-7 cells with pFD44 and each of the helper plasmids. Two days after transfection, rMVMp ministocks were prepared (crude cell extracts resulting from the transfection of 2 × 10 5 COS-7 cells) and the titer of each virus ministock was evaluated by replication center assay (RCA) 2 on NB324K indicator cells, a SV40-transformed newborn human kidney cell line, 21 by means of a CATspecific 32 P-labeled probe. Both helper plasmids displayed an essentially similar packaging ability (pSP116 + pFD44 versus pHVR4 + pFD44, range: 3.5-5.7 × 10 6 IU/ml versus 0.7-4.5 × 10 6 IU/ml) In another small-scale packaging assay, we showed that the final helper construct pHVR5 behaved essentially like its parent pHVR4 (data not shown), indicating that the genetically modified capsid genes were efficiently translated to functional viral proteins.
To compare their ability for virus DNA replication, the first-and second-generation vector genomes were introduced by transfection into COS-7 cells and low molecular weight DNA was analyzed by Southern blotting 2 days later. Figure 3 shows that all but pMN10 were able to efficiently replicate their DNA. Importantly, the two vector constructs devoid of the third NS2 exon (pME3 and pMN33) and the small central intron were able to replicate their DNA as efficiently as the vectors carrying the small central intron and expressing the entire NS2 geneproduct (pFD44, pMN18).
All second-generation vector genomes, including the NS2-truncated vectors pME3 and pMN33, did essentially behave like the parent vector pFD44, as regards P38-driven CAT expression after transfection in COS-7 cells and oncoselective gene transduction in SV40-transformed human fibroblasts (NB324K cells) versus normal fibroblasts (data not shown).
The packaging ability of first-and second-generation vectors was compared in purified, medium-scale (ෂ5 × 10 7 IU/ml) vector stocks. COS-7 cells were cotransfected with the new helper pHVR5 and each of the different vectors. Two days after transfection, the cells were harvested, the viruses were purified and concentrated as previously described 6 and the yield of recombinant vectors was assessed by RCA, using a CAT-specific 32 P-lab- eled probe. Figure 4 (hatched box) shows that the packaging ability of all vector genomes was essentially similar. It should be noted that pME3 yielded slightly, but reproducibly lower, amounts of rMVMp than the parental vector pFD44 (ෂ3 ×), a behavior that would result from the deletion of the third NS2 exon. However, no significant reduction of the packaging ability was observed with pMN33, which carries the same deletion of NS2.
Evaluation of helper virus contamination in recombinant vector stocks produced with the different vector constructs The level of contamination by helper-derived viruses in the medium-scale vector stocks described above was assessed by RCA, using a VP-specific 32 P-labeled probe ( Figure 4 , solid box). As expected, high levels of helper virus contamination (31%) were observed with the firstgeneration vector system, pFD44/pSP116 (Figure 4a) . Contamination was about the same (33%, data not shown) when the new vector pMN33 was used with the original helper pSP116. When the new helper plasmid pHVR5 was used with the first-generation vector pFD44 (Figure 4b ), contaminating helper virus production was reduced to only 0.39% (a 120-fold reduction with respect to pSP116/pFD44). This highlights the efficacy of reducing the size of the 5Ј overlap (from 797 to 373 nt) and limiting the sequence homology to about 60% in the 3Ј overlap. Partial modification of the vector genome by either entirely eliminating the 5Ј overlap (pME3) or reducing the 3Ј homologous sequence to only 74 bp (pMN18) did not further decrease contaminating helper virus production (0.34 and 0.32% for pME3 and pMN18, respectively). When the new vector and helper genomes were combined, contaminating helper virus production was further reduced (0.15% in rMVMp stocks at ෂ5 × 10 7 IU/ml as compared to 31% with the first-generation vector/helper system). Essentially similar contamination levels have been obtained in several independent midand large-scale rMVMp preparations using the newgeneration vector and helper constructs (data not shown). Our strategy was successful in reducing contamination (200 ×) of rMVMp stocks by contaminating helper viruses, but it did not completely prevent their production. Table 1 summarizes the results of a representative virus amplification experiment, showing the cytopathic effect (CPE) mediated by replication of lytic RCV and the RCV yield of the amplification process. As expected, wt MVMp induced a substantial CPE from the first step of virus amplification, suggesting considerable virus amplification. This was confirmed by the plaque assay at the second virus amplification step (limit of sensitivity of the assay = 1 IU, data not shown). The contaminating viruses generated from the first-generation pFD44 and pSP116 genomes behaved essentially like the wt virus, indicating that the viruses generated from this helper/vector genome pair can replicate autonomously. In contrast, the preparation obtained with the pMN33/pHVR5 pair displayed only a weak, transient CPE during primary infection, presumably linked to the high rMVMp content of the virus-containing inoculum (rMVMp expresses nonstructural genes whose products are cytotoxic), and no significant CPE after up to four rounds of amplification, suggesting the absence of detectable RCV in the vector stock. The absence of RCV was demonstrated by a sensitive plaque assay, after the fourth round of amplification. Results were confirmed either by 
Fate of contaminating viruses produced with the new vector systems
NB324K indicator cells were seeded at 3 × 10 5 per 5-cm diameter dish. The next day, the cells were infected with 1.5 × 10 3 IU wt MVMp or contaminating viruses in each rMVMp stock as determined by RCA with the VP probe. Two days later (before the massive cytopathic effect), the cells were harvested and crude cell lysates (first lysates) were prepared as previously described. 2 A second round of virus amplification (A2) was performed by infecting a series of fresh NB324K cultures with 1/10th (mock, II) or 1/1000th (wt, I) of the first cell lysates for 72 h, after which a new set of cell lysates was prepared (second lysates). Two further rounds of virus amplification (A3, A4) were performed for both mock-infected cultures and second generation-derived RCV, using 1/10th of the corresponding cell lysates at each step. Various dilutions of the second (wt, I) or the fourth (NI, II) lysates were used to assess wt virus and RCV amplification by plaque assay in NB324K cells. Each virus dilution was tested in duplicate. The virus-mediated cytopathic effect was evaluated before harvesting cells at each step of virus amplification. IU, infectious unit determined by RCA; CPE, cytopathic effect (−, no CPE; +, ++, increasing degree of cytotoxicity); PFU, plaque-forming unit; A1-4, rounds of virus amplification; NI, not infected; ND, not done; NA, not applicable; wt, wild-type MVMp; I, II, rMVMp derived from the first (pFD44+pSP116) or the second (pMN33+pHVR5) generation of vector and helper genomes, respectively. a Infectious virus (PFU) recovered from infected culture at indicated round of amplification.
Gene Therapy plaque assay, RCA or Southern blotting with at least three independent, large-scale rMVMp stocks generated using pMN33 and pHVR5 (data not shown).
In conclusion, these results show that the contaminating, helper-derived viruses generated from the newly designed vector/helper genomes pMN33 and pHVR5 do not generate autonomous virus propagation.
Discussion
Although significant progress has recently been made to optimize the construction and production of recombinant rodent autonomous parvoviruses, 6 ,12,14,22 current recombinant autonomous parvovirus stocks remain significantly contaminated by RCV. 3, 7, 12 To circumvent this problem, we have developed a strategy aiming to produce RCV-free recombinant virus stocks. To avoid the problem of homologous recombination, we have undertaken the construction of a new generation of vector and helper genomes with minimal sequence homology, by substantially reducing sequence overlaps and exploiting the degeneracy of the genetic code.
The left hand overlap was reduced to only 3 bp by directly inserting the transgene downstream to the 3Ј end of the NS1 gene in the vector construct. This resulted in skipping the third NS2 exon in the resulting vectors pME3 and pMN33. The vector pME3 was shown to behave essentially as the first-generation vector pFD44 with respect to viral DNA replication and oncoselective transgene expression. In contrast, its ability to produce recombinant particles was slightly reduced (three-fold). The reason for this defect is not clear. On the one hand, this might be due to deletion of as yet unknown cis-acting DNA sequences required for efficient virus production. On the other hand, Naeger et al 23 have shown that NS2 is required for efficient virus production at least in some cell types. Hence, the truncation and/or sequence alteration of the 3Ј end of NS2 might affect its activity. However, although a series of NS2 mutants of MVMp were severely defective in murine A9 cells, all mutants were found to replicate more efficiently and produce infectious virus in certain other cell types, including human NB324K and simian COS-1 cells. Moreover, the extent of the defect significantly varied depending on the location of the mutation in the molecule. In particular, NS2-2381, a mutant carrying a form of NS2 (ochre terminator after the first amino acid of the third NS2 exon) that is truncated similarly to that of pME3, was shown to form plaques in both murine and human or simian cell types essentially like the wt. 23 Finally, the production of rMVMp from pMN33 is not significantly reduced in comparison with pFD44, although it carries the same NS2 3Ј-end modification as pME3.
We were not able to completely remove the right hand homology because of the presence in this region of the cis-acting DNA replication elements previously described by Tam and Astell. Therefore, we have constructed a recombinant with minimal right sequence overlap while keeping all replication elements. This resulted in reduction of the right hand overlap with the helper genome to 74 nucleotides. Interestingly, Tam and Astell showed that replication of the DNA of a defective MVMp-based construct can be restored to normal by reinserting the replication elements (398 bp XbaI (4343)-Sau3A (4741) MVMp fragment) in either orientation. 17 We thus determined that it should be possible to restore DNA replication and still reduce vector-helper right sequence homology by reinserting this MVMp-specific fragment into pMN10 in the opposite orientation. This did not work, however. Indeed, results of preliminary experiments have shown that DNA replication can be fully restored in a pMN10-derived vector containing the MVMp-specific fragment inserted in the direct orientation (plasmid pMN54.22; Figure 1c ), but not in the vector with the same fragment inserted in the opposite orientation (plasmid pMN54.19; Figure 1c ) (Figure 3 , lane 4 versus 5). This discrepancy with Tam and Astell's data may be due, at least in part, to the fact that we used an MVMp-based genome nearly as large as the wild-type genome, whereas these authors used a minigenome of approximately 1.2 kb containing a large central deletion. We have previously found minigenomes to replicate more efficiently than ones of near-normal size. 34 When the new vector and helper genomes were used together for producing rMVMp, contaminating virus production was significantly reduced as compared with the first-generation vector/helper system (0.15% versus 31% in rMVMp stocks at ෂ5 × 10 7 IU/ml). It is noteworthy that in our preliminary experiments, small-scale virus stocks (crude cell extracts resulting from transfection of 2 × 10 5 COS-7 cells) were used to estimate RCA contamination by unwanted viruses. Surprisingly, no contaminating virus was detected in the rMVMp ministocks produced with the new packaging system (data not shown). This result was presumably due to some technical limitations inherent in the preparation of ministocks, suggesting that such small-scale virus preparations are not appropriate for the accurate titration of small amounts of virus. Our results clearly indicate that the major modifications present in the new vector/helper system are not sufficient to completely prevent recombination leading to the presence of contaminating helper virus. Since the remaining sequence homology between the new vector and helper genomes is very low, our results suggest that the contaminating viruses were generated by non-homologous recombination, as previously demonstrated for other advanced viral vector systems, including those based on retroviruses, AAV, and other autonomous parvoviruses such as LuIII. 9, 11, 24, 25 Interestingly, nonhomologous recombination has also been implicated in the formation of the deletions known to arise spontaneously at a high rate in the MVMp genome. 26, 27 Sequence analysis of the 5Ј and 3Ј recombination junctions should enable us to evaluate the relative contributions of the two recombination mechanisms in the production of contaminating helper genomes in our system. The 3Ј recombination junction is of particular interest, since a partially homologous (61%) 74-bp overlap remains in this region.
By using a sensitive sequential amplification assay, we have shown that helper viruses produced with the highly homologous first-generation packaging system behaved like true RCV, but those generated from the new packaging system cannot propagate autonomously in permissive cells. The inability of these contaminating viruses to replicate autonomously suggests that they are at least partially defective. The sequential virus amplification procedure associated with the plaque assay detects only viruses that can spread easily to fresh cultures, ie ones carrying all the cis-and trans-acting viral determinants required for the parvoviral life cycle. In contrast, the RCA method used to evaluate helper virus contamination after the primary infection detects particles containing at least the cis-acting sequences required for viral DNA replication (viral genomic ends) and a sequence complementary to the specific probe used to reveal the presence of contaminating viruses (VP genes). RCA detection of VP sequences in contaminating viral genomes does not mean that the VP genes are properly expressed. Furthermore, NS − genomes are also detectable by this method, since NS proteins can be provided in trans by co-infecting rMVMp present in excess in the vector stocks (ෂ99.9%).
In the new packaging system, the potential zones of recombination between the helper and vector genomes are functionally essential viral DNA sequences. The sequence of the upstream potential recombination zone contains: (1) the 3Ј-end of the NS genes (required in trans for both viral DNA replication and P38 transactivation); (2) the 5Ј-end of the capsid genes, including the small central intron responsible for differential expression of VP1 and VP2 (both being required for production of infectious parvoviral particles). 28 As for the downstream recombination zone that presumably lies in the region of the partially homologous 74-bp overlap, it contains the 3Ј-end of the capsid genes and a cis-acting element required for viral DNA replication. Modification of any of these critical cis/trans-acting DNA sequences should interfere with viral gene expression and/or DNA replication. Since most non-homologous recombination events presumably occur at unpredictable sites in the vector/helper genomes, it seems very unlikely that events affecting these important regions should give rise to functionally intact recombinant genomes. Such an occurrence cannot be ruled out, but we believe it should be highly infrequent. Systematic analysis of the RCV present in a large number of rMVMp stocks or having significant higher titers should enable us to test this view. In contrast, the extensive homology between the firstgeneration vector and helper genomes presumably allows highly efficient restoration of functional viral genomes by homologous recombination, explaining the abundance of RCV in first-generation rMVMp preparations.
Interestingly, Kestler et al 12 recently reported the construction and optimised production of new autonomous parvovirus vectors based on H1. To optimise the efficiency of vector production, a large fraction of the parvoviral genome was maintained in the vector construct. Consequently, the vector construct had a substantial sequence overlap with the helper genome (ෂ800 and ෂ1000 nt, respectively, on the left and on the right of the transgene). Yet, the level of RCV generated by this vector system remained relatively low (on the order of 0.15 29 to 1%) as compared with the level of RCV observed with our first-generation vector system. One possible explanation of this result is that human 293T cells used to package viral vectors in the work of Kestler et al are less recombinogenic than the simian COS cells used in our work. We plan to test this hypothesis by preparing rMVMp stocks in 293T and COS cells and by comparing the level of contaminating helper virus produced in both cell types. On the other hand, we also observed that the yield of RCV production can substantially vary as a function of the nature of the transgene inserted in a given vector backbone (ෂ0.4 and ෂ0.05% of helper-derived virus for pMVM/P38-cat (pFD44) and pMVM/P38-GFP, respectively). 3 As suggested before, 13, 14, 30 it should be possible to further reduce the frequency of recombination by limiting the number of helper genome copies present in the system. This means constructing a second-generation packaging cell line by stable integration of a small number of helper genome copies into the cell genome, rather than transient introduction of numerous copies by transfection.
The new MVMp-based vector system described here represents an important step in the development of autonomous parvovirus vectors. It should soon make it possible to produce rMVMp on a larger scale, to engineer second-generation packaging cell lines, and to assess the resulting rMVMp in vivo.
Materials and methods

Cells
The SV40-transformed simian cell line COS-7 (ATCC CRL-1651, Rockville, MD, USA) and the SV40-transformed newborn human kidney cell line NB324K 21 were grown in Dulbecco's modified Eagle's medium (Life Technologies, Merelbeke, Belgium) supplemented with 10% fetal calf serum (Sigma-Aldrich, Bornem, Belgium), l-glutamine (1 nm; Life Technologies), and antibiotics (Kanamycin; Life Technologies).
Plasmids
Plasmids used in this study are shown in Figure 1 . Standard recombinant DNA techniques were used for constructing most plasmids. 31 PCR amplifications were performed with Pwo DNA polymerase (Roche, Bruxelles, Belgium) and oligonucleotide primers purchased from Life Technologies. PCR-amplified fragments were first ligated into pCR-Script SK(+) (Stratagene, Amsterdam, The Netherlands) and sequenced with the Sequenase kit (Amersham-Pharmacia Biotech, Gent, Belgium) before their insertion into MVMp vector or helper constructs.
Gene Therapy
Vector plasmids containing undeleted right-hand MVM palindromic ends (5Ј with respect to the viral [−] DNA strand) were selected on the basis of the size of the wild type, undeleted 5Ј-terminal XbaI-BamHI fragment and propagated in the recBC sbcB recF strain JC8111. 32 First-generation vector and helper genomes: The vector plasmid pFD44 was previously described as pMVM/P38-cat. 2 Briefly, this vector was constructed by inserting the chloramphenicol acetyltransferase (CAT) reporter gene into the capsid-encoding region of pMM984, 5 between the HindIII and XbaI sites of the MVMp genome (nt 2651 to 4343). In this construct, a BglII site is located just upstream from the XbaI site.
The helper construct pSP116 was described previously as pP38-VP. 33 Briefly, this pBluescript II SK(+)-derived plasmid (Stratagene) contains the MVMp HaeIII-SspI (nt 1854-4629) fragment bearing the P38 promoter and both capsid genes linked to the SV40 early polyadenylation signal. In this construct, the MVMp insert is flanked at its 5Ј end by a BamHI site and at its 3Ј end by an NsiI site.
Second-generation vector and helper genomes: pHVR4 was constructed in four steps: (1) The 240 bp NotI-XhoI fragment of pSP116 containing the P38 promoter was replaced with the 973 bp BglII-XhoI (nt 13-986) fragment of pCDNA3 (Invitrogen, Groningen, The Netherlands) carrying the cytomegalovirus (CMV) major immediateearly gene promoter, generating pHVR1. The BglII and NotI sites of the pCDNA3-and pSP116-derived fragments respectively, were blunt-ended and ligated together, resulting in destruction of both sites. (2) A ෂ380 bp PCR fragment containing the small central intron of MVMp and a 5Ј portion of the VP genes (nt 2278-2651) was generated using the following oligonucleotide primers: 5Ј-GAGGGATCCAAGGTACGATGGCGCCTCCAGCTA AAAGAGC-3Ј (forward); 5Ј-GTAGCAAGCTTAGGTG CAAAAGCG CGCTTGG-3Ј (reverse). The resulting PCR fragment was digested with BamHI and HindIII and inserted in place of the 801-bp BamHI (nt 930 of pCDNA3)-HindIII (nt 2651 of MVMp genome) fragment and the 1346-bp HindIII-HindIII (nt 2651-3997 of MVMp) fragment from pHVR1, generating plasmid pHVR2. In this construct, a BamHI restriction site was placed just upstream of the 5Ј splice donor site (nt 2280) of the small central intron. (3) To restore the complete sequence of the VP genes, the 1346-bp HindIII-HindIII (nt 2651-3997) fragment of MVMp was inserted back into the HindIII site (nt 2651 of MVMp) of pHVR2, yielding plasmid pHVR3. (4) Finally, a PCR fragment containing the end of VP genes (nt 4343-4557 of MVMp) was generated using the following oligonucleotide primers: 5Ј-CTTTCTAGAATTGTTACATACGGTACATTTTTCTGG-3Ј (forward); 5Ј-GAGATGCATTTAGTAAGTATTTCTAGC AACAGGTC-3Ј (reverse). The resulting PCR fragment was digested with XbaI and NsiI and inserted in place of the 291-bp XbaI-NsiI fragment of pHVR3 comprising the end of the VP genes and a 3Ј nontranslated sequence, generating pHVR4. In this plasmid, the NsiI site was placed just downstream from the TAA codon of VP genes.
To construct pHVR5, the 3Ј end of the VP genes in pHVR4 was replaced with an altered but synonymous form of the same sequence. To replace the original codons, we chose synonymous codons used elsewhere in the MVMp genome. This strategy enabled us to reduce overall homology with the corresponding sequence of the vector DNA to ෂ60%. A sequence comprising the altered, synonymous form of the MVMp sequence from nt 4343 (XbaI site) to nt 4557 (stop codon of VP genes) was synthesized by R&D Systems Europe Ltd (Abingdon, UK). A NotI and a NsiI site were added to the 3Ј end of the sequence to allow subsequent cloning. The strategy adopted was to synthesize the different constituent oligonucleotides on Applied Biosystems 380B (Warrington, UK) synthesizers using standard cyanoethyl phosphoramidite chemistry. The oligonucleotides were then gel-purified and assembled into the full-length DNA sequence. The full-length sequence was subcloned into a pUC vector and the correct sequence was finally established by automated sequencing. The sequence of the synthesized XbaI-NsiI DNA fragment is available on request.
pMN10 was generated by ligating the 798-bp SspI-SalI fragment of pFD44 with the 8.2-kb SalI-XbaI fragment of pFD44. This resulted in elimination of a 286-bp XbaI-SspI fragment (nt 4343-4629 of MVMp) from pFD44. Ligation of the SspI site with the blunted XbaI site resulted in regeneration of the XbaI site.
pMN54.19 and pMN54.22 were constructed by inserting the 398 bp XbaI-Sau3AI (nt 4343-4741 of MVMp) fragment of pMM984 into the unique XbaI site of pMN10 in direct and reverse orientations, respectively. Both fragments were end-blunted before the ligation.
Plasmid pMN18 was constructed in two steps: a PCR fragment containing the MVMp DNA sequence from nt 4483 to 4740 was generated, using the following oligonucleotide primers: 5Ј-GAGAAGATCTGGTTACCAACTGC TACTGGAAACATGC-3Ј (forward); 5Ј-CTCTCTAGATT CTTATTCTATCTAACATTAACCAAC-3Ј (reverse). The resulting PCR fragment was then digested with BglII and XbaI and inserted into the corresponding sites of pMN10, generating pMN18. This modification resulted in deletion of the MVMp sequence from nt 2651 to 4483.
Plasmid pME3 was constructed as follows: a PCR fragment containing the 3Ј end of the NS1 gene (nt 2063-2280 of MVMp) was first generated using the following oligonucleotide primers: 5Ј-ATCGGATCTCGAGGACC TGGCTTTAGAGCC-3Ј (forward); 5Ј-CTCAAGCTTCTT AGTCCAAGTTCAGCGGCTC-3Ј (reverse).
Then, the resulting ෂ230-bp fragment was digested with XhoI and HindIII and inserted in place of the 580-bp XhoI-HindIII fragment (nt 2071-2651 of MVMp) of pFD44. This modification resulted in insertion of the CAT transgene via the HindIII site just downstream from the TAA codon of the NS1 gene. In pME3, the MVMp sequence from nt 2281 to 4341 was deleted.
The final vector genome pMN33 was generated by ligating the 7.8 kb SalI-BglII fragment of pME3 containing most of the prokaryotic vector pBR322 and the left part of the MVMp vector, including the CAT transgene, with the 1 kb BglII-SalI fragment of pMN18 carrying the remaining part of pBR322 and the right end of the viral vector. This resulted in deletion of the MVMp sequence from nt 2281 to 4483.
Transient replication assay COS-7 cells were seeded at 2 × 10 5 cells per 5-cm diameter dish. The next day, the cultures were transfected by the standard DNA/CaPO 4 co-precipitation method with 2 g of each vector construct and 8 g of pUC18 plasmid (to standardize the amount of DNA to 10 g of total DNA per dish). The cells were harvested 48 h after transfection and low molecular weight DNA was recovered by the Hirt procedure. One-tenth of each purified DNA was then digested with DpnI (in order to cut unreplicated, circular plasmids in small DNA fragments), fractionated by electrophoresis on a 1% agarose gel, transferred by Southern blotting to Hybond-N nylon membrane (Amersham-Pharmacia Biotech, Gent, Belgium) and finally hybridized to randomly primed, CAT-specific [␣-32 P]-labeled DNA probes.
Virus production and titration of recombinant virus stocks Small-scale rMVMp stocks were produced as described. 2 COS-7 cells were plated at 2 × 10 5 cells per 5-cm diameter dish. The next day, the cells were transfected by the standard co-precipitation method with 2 g of vector, 6 g of helper plasmid and 2 g of irrelevant plasmid DNA (pUC18). After 72 h, the cells were harvested and crude cell lysates were prepared in 500 l of hypotonic buffer (50 mm Tris-HCl, pH 8.7; 5 mm EDTA).
For mid-scale virus production, COS-7 cells were plated at 2 × 10 6 per 15-cm diameter dish. On the next day, the cultures were co-transfected with 20 g of vector and 40 g of helper plasmids. After 72 h, the cells were harvested and recombinant viruses were purified and concentrated as described. 6 Large-scale rMVMp stocks were obtained by pooling the cells from 10 mid-scale transfected cultures.
Wild-type MVMp, rMVMp and RCV titers of the different virus stocks were determined by RCA on the indicator cell line NB324K, using a 32 P-labeled specific probe (a 1.4 kb HindIII-XbaI CAT fragment derived from the vector construct pFD44 and a 769 bp BglII-BglII (nt 3450 to 4209) MVMp fragment derived from the capsid genes). 2 Sequential virus amplification for RCV detection NB324K indicator cells were seeded at 3 × 10 5 per 5-cm diameter dish. The next day, the cells were infected with wt MVMp or recombinant virus (1.5 × 10 3 IU with respect to wt MVMp or contaminating RCV in each rMVMp stock as determined by RCA with the VP probe). Two days later (before massive cytopathic effect), the cells were harvested and crude cell lysates were prepared. One tenth of each lysate was then used to infect a fresh dish of NB324K cells for a second round of amplification. Seventy-two hours later, cells of each culture were harvested and a second crude cell lysate was prepared to initiate the following round of virus amplification. This process was repeated for a total of four rounds of amplification. At the second and the fourth amplification step, a fraction of virus ministocks was used to perform a plaque assay or a RCA on NB324K cells to reveal the presence of RCV (the limit of sensitivity of the assay was 1 IU).
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